skip to Main Content

The State of Pharma Part VII: Marketing to Behavioral Healthcare Professionals

“The State of Pharma” series from HealthLink Dimensions has followed and examined trends that matter the most in pharma throughout the course of the pandemic. In this post, we examine how healthcare provider data can be used to reach behavioral…

The State of Pharma: Part VI

In our The State of Pharma series, HealthLink Dimensions has reported about trends shaping the pharmaceutical industry in the COVID-19 era. In this post, we examine how clinical trials were different due to the rapid pace of development for the…

The State of Pharma: Part V

In our The State of Pharma series, HealthLink Dimensions has examined how pharma brands can use email marketing to deliver important COVID-19 vaccine and therapy information to primary care physicians, marketing strategies to dermatologists, the importance of non-personal promotion during…

The State of Pharma: Part IV

In this series, HealthLink Dimensions has examined how pharma brands are marketing to dermatologists, the importance of non-personal promotion, and how pharma brands are evolving during the pandemic. In this post, we examine the value of using email marketing to…

The State of Pharma: Part III

In this series, HealthLink Dimensions has examined the importance of non-personal promotion (NPP) and how pharma brands are evolving during the pandemic and can prepare for the future. In this post, we look at how HealthLink Dimensions’ experience, valuable data,…

The State of Pharma: Part II

In this series, HealthLink Dimensions examines the effects of the COVID-19 pandemic on the pharmaceutical industry and what it means for the future of pharma marketing. At the beginning of the pandemic with in-person visits coming to a standstill, we saw many shifts in the…

The State of Pharma: Part I

The landscape of the pharmaceutical industry has changed this year with in-person promotion coming to a standstill. Marketing budgets are expected to be down for 46% of pharma companies, and 54% expect that drug launches will be delayed due to…

Back To Top